2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
04/24/18Exicure Announces Chief Executive Officer, Dr. David Giljohann, Named to Endpoints News’ “Under-40s” Biopharma Executives List
SKOKIE, Ill. – April 24, 2018 – Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, today announced that the Company's Chief Executive Officer, David Giljohann, Ph.D., has been recognized by Endpoints News as an outstanding up-and-coming biopharma professional under the age of 40.   Dr. Giljohann was Exicure's founding scientist in 2011. He has served as Chief Executive Officer since No... 
Printer Friendly Version
04/20/18Exicure Expands Leadership Team with Appointment of TLR9 Oncology Expert Matthias Schroff as Chief Operating Officer
CHICAGO, IL – April 20, 2018 – Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional spherical nucleic acid (SNA™) constructs, today announced the appointment of Matthias Schroff, Ph.D., to Chief Operating Officer. Dr. Schroff is a biotechnology industry veteran who brings more than 15 years of senior leadership experience within global biopharmaceutical companies where he gained deep scientific and clinical experience in immuno-oncology, TL... 
Printer Friendly Version
04/16/18Exicure to Present Data at the American Association for Cancer Research (AACR) 2018 Annual Meeting
SKOKIE, Ill. – April 16, 2018 – Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, announced today that it will present preclinical data in a poster session at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago, Illinois from April 14-18, 2018. The poster titled "TLR9 agonist SNA-induced innate and adaptive immune responses in tumor microenvironment enhance checkpoi... 
Printer Friendly Version
03/09/18Exicure, Inc. Reports Full Year 2017 Financial Results and Corporate Progress
Launched Phase 1 clinical trial of AST-008, a TLR9 agonist for immuno-oncologySKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, today reported full year financial results for the year ended December 31, 2017 and provided an update on corporate progress."Exicure is realizing the promise of our SNA technology through ongoing clinical advancements, including the launch of a ... 
Printer Friendly Version
01/31/18Exicure to Present at BIO CEO & Investor Conference, Immuno-Oncology 360° Summit and LEERINK Partners 7th Annual Global Healthcare Conference
SKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, today announced that Dr. David Giljohann, Chief Executive Officer of Exicure, will present a company update at the annual BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 1:45 pm EST at the New York Marriott Marquis in New York City. The company will also present at the Immuno-Oncology 360° Summit (IO360°... 
Printer Friendly Version
01/05/18Exicure, Inc. to Present at Biotech Showcase 2018
SKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, today announced that the company is scheduled to present at the 10th Annual Biotech Showcase conference held January 8-10, 2018 in San Francisco.Dr. David Giljohann, Chief Executive Officer of Exicure, will present a company overview on Tuesday, January 9th at 10:15 a.m. Pacific Time ... 
Printer Friendly Version

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet